Form 4: RA Capital Increases Stake in Artiva Biotherapeutics

RA Capital Management has significantly increased its beneficial ownership in Artiva Biotherapeutics through a series of open-market common stock purchases.

Summary

• RA Capital Management, L.P. acquired a total of 1,027,722 shares of Artiva Biotherapeutics (ARTV) common stock between June 9 and June 11, 2026.
• The purchases were executed at weighted average prices ranging from $6.91 to $7.91 per share.
• Following these transactions, the reporting entities hold a total of 16,231,717 shares in the aggregate across various managed funds and accounts.
• The filing confirms the reporting persons are 10% owners and hold board representation via Laura Stoppel.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a bullish signal, as significant open-market buying by a major institutional shareholder typically reflects high internal conviction in the company's pipeline and valuation.

Positives

• Strong signal of institutional confidence from a major healthcare-focused investment firm.
• Significant accumulation of shares indicates long-term commitment to the issuer's growth strategy.

Negatives

• Increased concentration of ownership by a single institutional investor may impact future liquidity or voting dynamics.

Risks

• Market volatility affecting the price of biotechnology equities.
• Regulatory and clinical trial risks inherent to the biopharmaceutical industry.

Future Outlook

No specific forward-looking guidance regarding company operations was provided; the filing reflects investment activity rather than operational updates.

Industry Context

StockSavvy.ai notes that aggressive accumulation by specialized healthcare funds like RA Capital often precedes or follows significant clinical milestones or strategic capital allocation events in the biotech sector.

Comparison to Industry Standards

• The activity is consistent with standard institutional portfolio management practices for life sciences venture firms.
• The ownership level confirms RA Capital's status as a cornerstone investor, similar to their roles in other clinical-stage biotech firms.

Stakeholder Impact

• Shareholders may view the increased institutional stake as a vote of confidence in the company's long-term prospects.

Next Steps

• Continued monitoring of SEC filings for further changes in beneficial ownership.
• Observation of upcoming clinical trial data or corporate announcements from Artiva Biotherapeutics.

Key Dates

Recommendation

While the insider buying is a positive signal, a 'hold' is recommended until further clinical or operational catalysts are confirmed to justify a higher valuation.

Keywords

Artiva Biotherapeutics, ARTV, RA Capital Management, Insider Trading, Biotech, SEC Form 4, Institutional Ownership